Hua Medicine Advances Glucose Homeostasis Platform at ADA 2026, Showcasing Dorzagliatin's Potential Across Metabolic Disease
Published on 06/09/2026 at 06:54 | japancorp.net
(HbA1c declined across all subgroups, with the greatest reduction observed in patients whose baseline TIR ?50%)
( TIR increased in the two subgroups with suboptimal baseline TIR, while the group with baseline TIR meeting the target maintained satisfactory TIR levels.)
?-cell function improved in all groups, with a marked elevation in HOMA-? seen in the subgroup with baseline TIR ?50%
This subgroup analysis of the 6-month interim results indicates that dorzagliatin provides meaningful efficacy in glycemic control among real-world T2D patients that are characterized by long duration of disease and high prevalence of combination therapy with multiple antidiabetic agents, including insulin. Even in patients with severely compromised baseline TIR, clinically meaningful reductions in HbA1c, improved TIR, enhanced ?-cell function, and reduced insulin resistance were observed, collectively indicating the restoration of glucose homeostasis.
III. Deep Integration of AI Builds an Integrated System for Precision Diabetes Classification, Prediction, and Care
By integrating artificial intelligence (AI), large language models (LLM), and clinical big data around the core GK mechanism, Hua Medicine has developed a full suite of AI tools for efficacy prediction, diabetes remission forecasting, monogenic diabetes classification, and intelligent medical education.
1.GK Charger: An LLMpowered interactive medical education platform that integrates molecular mechanisms, pharmacological profiles, clinical studies, guidelines, and realworld evidence. It translates complex GKrelated scientific concepts into clinically actionable and non-specialist-friendly evidencebased content for clinicians, researchers, patients, and the public, supporting scalable precision medical education and adoption of GKtargeted therapies.
2.Glycemic Control and Diabetes Remission Prediction Models: Clinicianoriented predictive tools built on dorzagliatin clinical data to estimate the probability of HbA1c response and diabetes remission after treatment. These webbased applications support personalized T2D management and precision medicine, with performance expected to improve as data accumulates.
3.AIPowered GK Variant Analysis System: A precision tool for MODY2 built on a database of approximately 1,000 GK variants, combining structural analysis, evolutionary modeling, and LLMs. It delivers 90% accurate predictions of variant location, functional impact, disease association, and dorzagliatin response in seconds, accelerating genetic diagnosis and targeted medication guidance for MODY2.
Hua Medicine also introduced a novel ATPindependent enzymatic cycling system for highly efficient glucose removal from biological samples without generating oxidative byproducts or depleting ATP, preserving native metabolome integrity. It enables accurate quantification of 1,5anhydroglucitol (1,5AG), a key marker for shortterm glycemic variability, supporting reliable and highthroughput precision diabetes testing.
Academic Recognition
Notably, Lingge Feng, Senior Director of Research and Discovery Technology at Hua Medicine, was awarded the ADA Early Career Abstract Award, earning recognition from the global diabetes research community. The award honors outstanding early-career investigators in the diabetes field who demonstrate exceptional academic potential and original contributions, representing an important official endorsement from the global diabetes community.
With long-standing expertise in dorzagliatin development and AIenabled precision diabetes therapeutics, this recognition not only reflects the scientific quality of Hua Medicine's research efforts, but also underscores the growing international academic recognition of Hua Medicine's cuttingedge work in innovative drug R&D and AIpowered diabetes care, further advancing innovative Chinese pharmaceutical research onto the world stage.
From combination therapies expanding metabolic disease indications, to realworld evidence validating longterm safety and efficacy, to AIdriven precision care and breakthrough diagnostic technologies, Hua Medicine's 2026 ADA data comprehensively validate the mechanistic uniqueness and broad clinical utility of dorzagliatin-the world's first commercialized GKA. Beyond Type 2 diabetes, these findings are expected to accelerate clinical development and label expansion into obesity, MASLD, MODY2, and other metabolic disorders to benefit broader patient populations.
This press release contains information that is in the public domain following presentation(s) at the 86th ADA Scientific Sessions. It is issued for informational purposes to shareholders, investors, analysts and healthcare professionals. Nothing in this release should be construed as investment advice. Where applicable, statements regarding future expectations, pipeline progression or regulatory timelines are forward-looking statements subject to risks and uncertainties - actual results may differ materially.
About Hua Medicine
Hua Medicine (The 'Company') is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for T2D patients with with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS') was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors: ir@huamedicine.com
Media: pr@huamedicine.com
Source: Hua Medicine
Copyright 2026 ACN Newswire . All rights reserved.
( TIR increased in the two subgroups with suboptimal baseline TIR, while the group with baseline TIR meeting the target maintained satisfactory TIR levels.)
?-cell function improved in all groups, with a marked elevation in HOMA-? seen in the subgroup with baseline TIR ?50%
This subgroup analysis of the 6-month interim results indicates that dorzagliatin provides meaningful efficacy in glycemic control among real-world T2D patients that are characterized by long duration of disease and high prevalence of combination therapy with multiple antidiabetic agents, including insulin. Even in patients with severely compromised baseline TIR, clinically meaningful reductions in HbA1c, improved TIR, enhanced ?-cell function, and reduced insulin resistance were observed, collectively indicating the restoration of glucose homeostasis.
III. Deep Integration of AI Builds an Integrated System for Precision Diabetes Classification, Prediction, and Care
By integrating artificial intelligence (AI), large language models (LLM), and clinical big data around the core GK mechanism, Hua Medicine has developed a full suite of AI tools for efficacy prediction, diabetes remission forecasting, monogenic diabetes classification, and intelligent medical education.
1.GK Charger: An LLMpowered interactive medical education platform that integrates molecular mechanisms, pharmacological profiles, clinical studies, guidelines, and realworld evidence. It translates complex GKrelated scientific concepts into clinically actionable and non-specialist-friendly evidencebased content for clinicians, researchers, patients, and the public, supporting scalable precision medical education and adoption of GKtargeted therapies.
2.Glycemic Control and Diabetes Remission Prediction Models: Clinicianoriented predictive tools built on dorzagliatin clinical data to estimate the probability of HbA1c response and diabetes remission after treatment. These webbased applications support personalized T2D management and precision medicine, with performance expected to improve as data accumulates.
3.AIPowered GK Variant Analysis System: A precision tool for MODY2 built on a database of approximately 1,000 GK variants, combining structural analysis, evolutionary modeling, and LLMs. It delivers 90% accurate predictions of variant location, functional impact, disease association, and dorzagliatin response in seconds, accelerating genetic diagnosis and targeted medication guidance for MODY2.
Hua Medicine also introduced a novel ATPindependent enzymatic cycling system for highly efficient glucose removal from biological samples without generating oxidative byproducts or depleting ATP, preserving native metabolome integrity. It enables accurate quantification of 1,5anhydroglucitol (1,5AG), a key marker for shortterm glycemic variability, supporting reliable and highthroughput precision diabetes testing.
Academic Recognition
Notably, Lingge Feng, Senior Director of Research and Discovery Technology at Hua Medicine, was awarded the ADA Early Career Abstract Award, earning recognition from the global diabetes research community. The award honors outstanding early-career investigators in the diabetes field who demonstrate exceptional academic potential and original contributions, representing an important official endorsement from the global diabetes community.
With long-standing expertise in dorzagliatin development and AIenabled precision diabetes therapeutics, this recognition not only reflects the scientific quality of Hua Medicine's research efforts, but also underscores the growing international academic recognition of Hua Medicine's cuttingedge work in innovative drug R&D and AIpowered diabetes care, further advancing innovative Chinese pharmaceutical research onto the world stage.
From combination therapies expanding metabolic disease indications, to realworld evidence validating longterm safety and efficacy, to AIdriven precision care and breakthrough diagnostic technologies, Hua Medicine's 2026 ADA data comprehensively validate the mechanistic uniqueness and broad clinical utility of dorzagliatin-the world's first commercialized GKA. Beyond Type 2 diabetes, these findings are expected to accelerate clinical development and label expansion into obesity, MASLD, MODY2, and other metabolic disorders to benefit broader patient populations.
This press release contains information that is in the public domain following presentation(s) at the 86th ADA Scientific Sessions. It is issued for informational purposes to shareholders, investors, analysts and healthcare professionals. Nothing in this release should be construed as investment advice. Where applicable, statements regarding future expectations, pipeline progression or regulatory timelines are forward-looking statements subject to risks and uncertainties - actual results may differ materially.
About Hua Medicine
Hua Medicine (The 'Company') is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for T2D patients with with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS') was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors: ir@huamedicine.com
Media: pr@huamedicine.com
Source: Hua Medicine
Copyright 2026 ACN Newswire . All rights reserved.
en | CA7609751028 | HUA MEDICINE | boerse | 69504964 |
